These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15069988)

  • 1. Pricing and costs of drugs in the United States and Sweden: a comparison based on drug acquisition costs at the patient outcome level.
    Melander A; Nilsson JL
    J Ambul Care Manage; 2004; 27(2):115-9. PubMed ID: 15069988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker.
    Okano GJ; Rascati KL; Wilson JP; Remund DD; Grabenstein JD; Brixner DI
    Clin Ther; 1997; 19(6):1433-45; discussion 1424-5. PubMed ID: 9444451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure.
    Siegel D; Lopez J
    JAMA; 1997 Dec; 278(21):1745-8. PubMed ID: 9388150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
    Sakamaki Y; Sasamura H; Ikeda S; Ikegami N; Saruta T
    Hypertens Res; 2006 May; 29(5):333-8. PubMed ID: 16832153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
    Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
    Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
    Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
    Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The retail cost of antihypertensive therapy. Physician and patient as educated consumers.
    Reif MC; Carter VL
    Am J Hypertens; 1994 Jul; 7(7 Pt 1):571-5. PubMed ID: 7946156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care.
    Schäfer HH; Scheunert U
    Swiss Med Wkly; 2013; 143():w13854. PubMed ID: 24163048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in medical expenditure according to drug prices.
    Ueshima H
    Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
    [No Abstract]   [Full Text] [Related]  

  • 11. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice.
    Fretheim A; Aaserud M; Oxman AD
    PLoS Med; 2006 Jun; 3(6):e216. PubMed ID: 16737349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension.
    Xu KT; Moloney M; Phillips S
    Am J Manag Care; 2003 Aug; 9(8):529-36. PubMed ID: 12921230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of prescription antihypertensive drug utilization and adherence to treatment guidelines in the city of Novi Sad.
    Tomas A; Tomić Z; Milijasević B; Ban M; Horvat O; Vukmirović S; Sabo A
    Vojnosanit Pregl; 2016 Jun; 73(6):531-7. PubMed ID: 27498444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of national guidelines on antihypertensive prescribing patterns.
    Siegel D
    Curr Hypertens Rep; 2000 Jun; 2(3):247-52. PubMed ID: 10981157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coverage of drug costs: reference-based pricing.
    McGregor M
    Can J Cardiol; 1998 May; 14(5):666-8. PubMed ID: 9627520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Your money or their life. Drug to combat blood pressure may come at a price, but the wider health benefits should not be underestimated, says Nick Summerton.
    Summerton N
    Health Serv J; 2004 Jul; 114(5914):24-5. PubMed ID: 15290879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of antihypertensive drugs in Spain, 1985-1995].
    Prieto M; de Abajo FJ; Montero D; Martín-Serrano G; Madurga M; Palop R
    Med Clin (Barc); 1998 Feb; 110(7):247-53. PubMed ID: 9562948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the phamacologic treatment of hypertension in the Department of Veterans Affairs 1997-1999: decreased use of calcium antagonists and increased use of beta-blockers and thiazide diuretics.
    Siegel D; Lopez J; Meier J; Cunningham F
    Am J Hypertens; 2001 Sep; 14(9 Pt 1):957-62. PubMed ID: 11587164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a computer-based decision support system for treatment of hypertension with drugs: retrospective, nonintervention testing of cost and guideline adherence.
    Persson M; Mjörndal T; Carlberg B; Bohlin J; Lindholm LH
    J Intern Med; 2000 Jan; 247(1):87-93. PubMed ID: 10672135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
    Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB
    N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.